The present study aimed to examine whether the APOE ε4 allele, associated with dementia with Lewy bodies (DLB), and possibly with dementia in Parkinson's disease (PD), is also associated with idiopathic rapid eye movement sleep behavior disorder (RBD). Two single nucleotide polymorphisms, rs429358 and rs7412, were genotyped in RBD patients (n ¼ 480) and in controls (n ¼ 823). APOE ε4 allele frequency was 0.14 among RBD patients and 0.13 among controls (OR ¼ 1.11, 95% CI: 0.88e1.40, p ¼ 0.41). APOE ε4 allele
a b s t r a c t
The present study aimed to examine whether the APOE ε4 allele, associated with dementia with Lewy bodies (DLB), and possibly with dementia in Parkinson's disease (PD), is also associated with idiopathic rapid eye movement sleep behavior disorder (RBD). Two single nucleotide polymorphisms, rs429358 and rs7412, were genotyped in RBD patients (n ¼ 480) and in controls (n ¼ 823). APOE ε4 allele frequency was 0.14 among RBD patients and 0.13 among controls (OR ¼ 1.11, 95% CI: 0.88e1.40, p ¼ 0.41). APOE ε4 allele Keywords: APOE REM sleep behavior disorder Genetics Parkinson's disease Dementia with Lewy bodies frequencies were similar in those who converted to DLB (0.14) and those who converted to Parkinson's disease (0.12) or multiple system atrophy (0.14, p ¼ 1.0). The APOE ε4 allele is neither a risk factor for RBD nor it is associated with conversion from RBD to DLB or other synucleinopathies.
Ó 2016 Elsevier Inc. All rights reserved.
Introduction
Rapid eye movement (REM) sleep behavior disorder (RBD) is currently the strongest clinical prodromal feature preceding the development of an overt synucleinopathy, including Parkinson's disease (PD), dementia with Lewy bodies (DLB) or multiple system atrophy (MSA) (Iranzo et al., 2014) . One of the strongest genetic factors associated with DLB is the APOE epsilon4 (ε4) allele (Pickering-Brown et al., 1994) , and PD patients who carry this allele may be at increased risk for developing dementia. Since both RBD and the APOE ε4 allele are possibly associated with DLB, and with dementia in PD patients, we aimed to examine whether the APOE ε4 allele is associated with RBD and conversion to DLB. See Supplementary Material for detailed introduction and full list of references.
Methods
The study population included idiopathic RBD patients (n ¼ 480) and controls (n ¼ 823) of European ancestry. RBD patients were diagnosed using clinical interview and polysomnography according to the International Classification of Sleep Disorders, Version 2 criteria. The control group was composed of 253 elderly controls (age 59.5 AE 9.8 years, matched to the available age at onset (AAO) of RBD, n ¼ 307, age 59.2 AE 11.5), 510 young controls (age 34.0 AE 6.5 years), and additional 60 controls with no available data on age. All control groups had nearly identical frequencies of the APOE ε4 allele (0.13, 0.13, and 0.14, respectively), which allowed us to analyze all controls combined. All individuals signed informed consent forms at enrollment, and the study protocols were approved by the respective institutional review boards. DNA was extracted using a standard salting-out protocol. Two single nucleotide polymorphisms, rs429358 and rs7412, were genotyped using TaqMan single nucleotide polymorphism genotyping assays. Genotypes were called using the QuantStudio 7 Flex Real-Time PCR System and Software (V 1.0). Goodness of fit test with 1 degree of freedom was applied to look for deviation from the HardyeWeinberg equilibrium among the controls. Differences in APOE allele or carriage frequencies were analyzed using the Fisher's exact test, and differences in continuous variables were analyzed using t test. A logistic regression model with age and sex as covariates was also applied. All statistical analysis was done using SPSS statistics V.23 (IBM Inc). Detailed methods can be found in the Supplementary Material.
Results
The allele frequency of APOE ε4 was 0.14 among RBD patients and 0.13 among controls (OR ¼ 1.11, 95% CI: 0.88e1.40, p ¼ 0.41). Overall, 25.8% of RBD patients carried at least 1 APOE ε4 compared to 23.0% among controls (p ¼ 0.25, Fisher's exact test), and there were more homozygous carriers of the APOE ε4 allele among controls (3.2%) as compared to RBD patients (2.7%). Logistic regression model adjusted for age and sex also demonstrated lack of association between APOE ε4 allele carriage and risk for RBD (OR ¼ 1.25, 95% CI: 0.87e1.79, p ¼ 0.23). There was no difference in AAO when comparing carriers (n ¼ 88) and noncarriers (n ¼ 219) of the APOE ε4 allele (59.1 AE 8.4 vs. 59.3 AE 12.6 years, respectively, p ¼ 0.92, t test). A total of 140 RBD patients (29.2%) were reported to have converted to either PD (n ¼ 98, 70% of the converters), dementia/DLB (n ¼ 28, 20%), or MSA (n ¼ 14, 10%). The carrier frequencies of one or more APOE ε4 in these groups were similar; 23.5%, 25.0%, and 28.6%, respectively (p ¼ 0.91), and the allele frequencies were 0.12, 0.14, and 0.14 (p ¼ 1.0). The APOE ε4 allele frequency among those that did not convert was slightly higher, 0.15 (Table 1) , with a total of 26.5% carriers of at least one APOE ε4 allele, compared to 24.3% among those who converted (p ¼ 0.65). More detailed results can be found in the Supplementary Material.
Discussion
Although RBD is a strong risk factor for developing DLB and although DLB was reported to be associated with the APOE ε4 allele, our results demonstrate lack of association between the APOE ε4 allele and RBD or its AAO. These and previous results further suggest that RBD may have a distinct genetic background; it is associated with GBA mutations (Gan-Or et al., 2015b) , but unlike PD, it is not associated with LRRK2 mutations (Fernandez-Santiago et al., 2016) , and unlike DLB, it is not associated with the APOE ε4 allele. Thus far, GBA, SCARB2, and potentially SNCA (Gan-Or et al., 2015a) overlap between RBD, PD, and DLB (Supplementary Material). Whether RBD has additional, unique genetic factors that were not identified in PD or DLB cohorts is still to be determined. Our present study identified similar frequencies of APOE ε4 allele in those who progressed to PD, DLB, and MSA, suggesting that APOE alleles do not affect the type of subsequent synucleinopathy. Our study has some limitations, and a more detailed discussion including full list of references can be found in the Supplementary Material. Our results support a distinct genetic background for RBD-associated Table 1 APOE haplotypes in individuals with RBD and controls APOE ε2/ε2, n, (%) ε2/ε3, n, (%) ε3/ε3, n, (%) ε2/ε4, n, (%) ε3/ε4, n, (%) ε4/ε4, n, (%) Total carriers of ε4, n (%) 
